[go: up one dir, main page]

MX2019006221A - Preparacion de complejos solidos de ciclodextrina para suministro de ingredientes farmaceuticos activos oftalmicos. - Google Patents

Preparacion de complejos solidos de ciclodextrina para suministro de ingredientes farmaceuticos activos oftalmicos.

Info

Publication number
MX2019006221A
MX2019006221A MX2019006221A MX2019006221A MX2019006221A MX 2019006221 A MX2019006221 A MX 2019006221A MX 2019006221 A MX2019006221 A MX 2019006221A MX 2019006221 A MX2019006221 A MX 2019006221A MX 2019006221 A MX2019006221 A MX 2019006221A
Authority
MX
Mexico
Prior art keywords
preparation
active pharmaceutical
pharmaceutical ingredient
cyclodextrin complexes
ingredient delivery
Prior art date
Application number
MX2019006221A
Other languages
English (en)
Other versions
MX389363B (es
Inventor
Loftsson Thorsteinn
Fulop Zoltan
Original Assignee
Oculis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61656066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019006221(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oculis SA filed Critical Oculis SA
Publication of MX2019006221A publication Critical patent/MX2019006221A/es
Publication of MX389363B publication Critical patent/MX389363B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgacion se relaciona con composiciones oftalmicas que contienen complejos solidos de ingrediente activo farmaceutico y ciclodextrina, con su metodo de preparacion y sus usos; las composiciones pueden incluir un complejo de farmaco de agente activo / ciclodextrina sustancialmente disuelto en un vehiculo acuoso de gotas oftalmicas; la composicion oftalmica esta generalmente en la forma de una microsuspension que incluye un complejo de agente activo que tiene un diametro menor a aproximadamente 100 µm.
MX2019006221A 2016-11-29 2017-11-29 Preparacion de complejos solidos de ciclodextrina para suministro de ingredientes farmaceuticos activos oftalmicos MX389363B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427737P 2016-11-29 2016-11-29
PCT/IB2017/001659 WO2018100434A1 (en) 2016-11-29 2017-11-29 Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery

Publications (2)

Publication Number Publication Date
MX2019006221A true MX2019006221A (es) 2019-10-07
MX389363B MX389363B (es) 2025-03-20

Family

ID=61656066

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006221A MX389363B (es) 2016-11-29 2017-11-29 Preparacion de complejos solidos de ciclodextrina para suministro de ingredientes farmaceuticos activos oftalmicos

Country Status (31)

Country Link
US (7) US11135311B2 (es)
EP (2) EP4194011A1 (es)
JP (2) JP7138103B2 (es)
KR (3) KR102774277B1 (es)
CN (2) CN117018220A (es)
AR (2) AR110269A1 (es)
AU (1) AU2017369971B2 (es)
CA (1) CA3045226A1 (es)
CL (1) CL2019001447A1 (es)
CO (1) CO2019005729A2 (es)
CY (1) CY1124917T1 (es)
DK (1) DK3548091T3 (es)
EA (1) EA201991299A1 (es)
ES (1) ES2903383T3 (es)
HR (1) HRP20220046T1 (es)
HU (1) HUE057221T2 (es)
IL (2) IL266964B2 (es)
LT (1) LT3548091T (es)
MA (1) MA46997B1 (es)
MD (1) MD3548091T2 (es)
MX (1) MX389363B (es)
PH (1) PH12019550088A1 (es)
PL (1) PL3548091T3 (es)
PT (1) PT3548091T (es)
RS (1) RS62845B1 (es)
SI (1) SI3548091T1 (es)
SM (1) SMT202200025T1 (es)
TW (2) TWI810167B (es)
UA (1) UA124774C2 (es)
WO (1) WO2018100434A1 (es)
ZA (1) ZA201903307B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991299A1 (ru) * 2016-11-29 2019-11-29 Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
IT201900000561A1 (it) * 2019-01-14 2020-07-14 Medivis S R L Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac
CN110051859B (zh) * 2019-06-06 2020-06-12 鲁南制药集团股份有限公司 一种阿昔替尼环糊精包合物
AU2020298754B2 (en) 2019-07-01 2025-06-26 Oculis Operations Sàrl Method for stabilizing the pH of an aqueous composition comprising a drug
TWI756547B (zh) * 2019-07-15 2022-03-01 高雄榮民總醫院 奈米眼藥水及其製造方法
CN115484957B (zh) * 2020-04-24 2024-06-21 兰泰克生物技术公司 用于治疗眼部状况的制剂
US20230263907A1 (en) * 2020-06-30 2023-08-24 Oculis SA Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
CN111728953B (zh) * 2020-07-29 2023-08-08 中国科学院上海药物研究所 一种托法替布或其盐的缓释制剂及其制备方法
KR102489633B1 (ko) * 2021-01-21 2023-01-17 주식회사태준제약 점안 조성물
US20240299291A1 (en) * 2021-01-22 2024-09-12 Chengdu Ruimu Biopharmaceuticals Co., Ltd. Ophthalmic preparation administered by eye drops and used for preventing and treating dry macular degeneration and retinal light damage
US11998562B2 (en) * 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
CN117881411A (zh) * 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
US20240350402A1 (en) * 2021-08-31 2024-10-24 The Cleveland Clinic Foundation Topical drug treatment to prevent or reduce corneal scarring
EP4398898A4 (en) * 2021-09-09 2025-07-02 Biora Therapeutics Inc AQUEOUS FORMULATIONS OF TOFACITINIB AND TOFACITINIB SALTS
WO2023132947A1 (en) * 2022-01-05 2023-07-13 The Regents Of The University Of California Closo-dodecaiododecaborate complexes and methods of use for same
CA3250770A1 (en) 2022-02-02 2023-08-10 Oculis Operations Sarl MULTIDOSE OPHTHALMIC COMPOSITIONS
KR20240159823A (ko) * 2023-04-28 2024-11-06 비바비젼 바이오테크 엘티디 비감염성 염증성 질환의 치료를 위한 안과 조성물
CN118892544A (zh) * 2023-04-28 2024-11-05 维眸生物科技(浙江)有限公司 一种用于治疗非感染性炎症疾病的眼科组合物
TW202508583A (zh) * 2023-08-28 2025-03-01 碩德生技股份有限公司 低溶解度物質的眼用組合物之製備方法
WO2025082585A1 (en) 2023-10-16 2025-04-24 Oculis Operations Sàrl Method of treating diabetic macular edema
WO2025083031A1 (en) 2023-10-16 2025-04-24 Oculis Operations Sàrl Method of treating diabetic macular edema
WO2025169089A1 (en) 2024-02-05 2025-08-14 Sun Pharmaceutical Industries Limited Ophthalmic compositions of tyrosine kinase inhibitors and their uses
KR102838026B1 (ko) * 2024-04-30 2025-07-28 주식회사 스카이테라퓨틱스 액시티닙 신규 분자 회합체를 포함하는 점안 조성물 및 이의 제조방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
JPS60149530A (ja) 1984-01-13 1985-08-07 Takeda Chem Ind Ltd 水性製剤
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
DK0642332T3 (da) 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
EP0709099A3 (en) 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
TW434023B (en) 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JP4215277B2 (ja) 1996-08-09 2009-01-28 アルコン ラボラトリーズ，インコーポレイテッド シクロデキストリンを含有する薬学的組成物用防腐剤系
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
HRP20010309B1 (en) 1998-12-23 2005-06-30 Idea Ag Improved formulation for topical non-invasive application in vivo
DE19957788A1 (de) 1999-12-01 2001-07-05 Schott Glas Tropfflasche
DE10036871A1 (de) 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
CA2428189A1 (en) * 2000-11-15 2002-05-23 Mainde Chandrashekhar Pharmaceutival preparations comprising corticosteroids and antiinfective agents
WO2004069280A1 (en) 2003-02-06 2004-08-19 Cipla Ltd Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent
CA2516429A1 (en) * 2003-02-21 2004-10-14 Sun Pharmaceutical Industries Limited Stable ophthalmic formulation containing an antibiotic and a corticosteroid
KR20060011943A (ko) 2003-03-28 2006-02-06 아이박스 코포레이션 향상된 경구 및 경점막 수송용 클라드리빈 제형
ATE444732T1 (de) 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
CN1559413A (zh) 2004-02-26 2005-01-05 胡秀爱 地塞米松磷酸钠冻干粉针及制备方法
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US6969706B1 (en) 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
US20080145430A1 (en) 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
CN100584332C (zh) 2004-12-08 2010-01-27 胡世兴 含有粉防己碱的眼用制剂及其在制备治疗眼科疾病的含有粉防己碱的眼用制剂中的应用
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
WO2008057360A1 (en) 2006-11-02 2008-05-15 Riolan Technologies, Inc. Methods of treating an ocular allergy with low dose dexamethasone
ES2493641T3 (es) 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8524267B2 (en) 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
CN101926760A (zh) 2009-06-24 2010-12-29 天津金耀集团有限公司 2-羟丙基-β-环糊精包合地塞米松注射液
JP5810098B2 (ja) 2010-12-28 2015-11-11 ロート製薬株式会社 水性眼科組成物
US20140163080A1 (en) * 2011-02-03 2014-06-12 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
SMT202400264T1 (it) * 2012-05-08 2024-07-09 Onyx Therapeutics Inc Metodi di complessazione di ciclodestrina per formulare inibitori del proteasoma peptidico
KR101475776B1 (ko) 2012-08-24 2014-12-24 영진약품공업 주식회사 이중 포화 인지질을 포함하는 안정한 피부 외용 조성물
CA2914472C (en) * 2012-08-24 2019-09-03 Ashim K. Mitra Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
CA2986297A1 (en) 2015-05-29 2016-12-08 Oculis ehf. Formation of cyclosporin a/cyclodextrin nanoparticles
WO2017083799A1 (en) 2015-11-13 2017-05-18 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. COMBINATION TREATMENT OF FLAMMABLE CONDITIONS AND DISEASES OF THE EYE
EA201991299A1 (ru) * 2016-11-29 2019-11-29 Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
US11000530B2 (en) 2017-09-01 2021-05-11 Murray And Poole Enterprises Ltd Methods and compositions for the treatment of ophthalmic conditions
US20190105264A1 (en) 2017-10-06 2019-04-11 Aciont Inc. Non-invasive ocular drug delivery devices
CN111670036B (zh) 2018-01-31 2024-08-09 安成生物科技股份有限公司 包含托法替尼的局部调配物
SG11202106967QA (en) 2018-12-27 2021-07-29 Surface Ophthalmics Inc Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
AU2020298754B2 (en) * 2019-07-01 2025-06-26 Oculis Operations Sàrl Method for stabilizing the pH of an aqueous composition comprising a drug
EA202290086A1 (ru) * 2020-05-12 2022-03-18 Окюлис Са СПОСОБ СТАБИЛИЗАЦИИ рН ВОДНОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ЛЕКАРСТВЕННОЕ СРЕДСТВО
CA3250770A1 (en) * 2022-02-02 2023-08-10 Oculis Operations Sarl MULTIDOSE OPHTHALMIC COMPOSITIONS
CN115837027A (zh) 2022-11-15 2023-03-24 中国药科大学 一种眼用地塞米松药物组合物

Also Published As

Publication number Publication date
AR110269A1 (es) 2019-03-13
PT3548091T (pt) 2022-01-21
IL266964A (en) 2019-07-31
EP3548091A1 (en) 2019-10-09
KR20240036731A (ko) 2024-03-20
EP3548091B1 (en) 2021-12-01
CN110177576B (zh) 2023-08-11
EP4194011A1 (en) 2023-06-14
PH12019550088A1 (en) 2020-06-15
HRP20220046T1 (hr) 2022-04-15
IL310360A (en) 2024-03-01
WO2018100434A1 (en) 2018-06-07
JP2019535798A (ja) 2019-12-12
SI3548091T1 (sl) 2022-04-29
TWI773706B (zh) 2022-08-11
DK3548091T3 (da) 2022-01-17
MA46997B1 (fr) 2022-01-31
CN110177576A (zh) 2019-08-27
CA3045226A1 (en) 2018-06-07
TWI810167B (zh) 2023-08-01
SMT202200025T1 (it) 2022-05-12
UA124774C2 (uk) 2021-11-17
US20230042785A1 (en) 2023-02-09
US11135311B2 (en) 2021-10-05
AR110270A1 (es) 2019-03-13
CO2019005729A2 (es) 2019-08-30
US20240091377A1 (en) 2024-03-21
US20190343846A1 (en) 2019-11-14
AU2017369971B2 (en) 2023-06-01
KR20230025939A (ko) 2023-02-23
MX389363B (es) 2025-03-20
TW201825100A (zh) 2018-07-16
ES2903383T3 (es) 2022-04-01
AU2017369971A1 (en) 2019-06-13
IL266964B1 (en) 2024-02-01
JP2022172291A (ja) 2022-11-15
LT3548091T (lt) 2022-02-10
US20220008555A1 (en) 2022-01-13
US20250177561A1 (en) 2025-06-05
US20180147297A1 (en) 2018-05-31
HUE057221T2 (hu) 2022-04-28
IL266964B2 (en) 2024-06-01
CN117018220A (zh) 2023-11-10
CY1124917T1 (el) 2023-01-05
BR112019011067A2 (pt) 2019-12-17
JP7138103B2 (ja) 2022-09-15
KR102525438B1 (ko) 2023-04-26
PL3548091T3 (pl) 2022-03-28
EA201991299A1 (ru) 2019-11-29
RS62845B1 (sr) 2022-02-28
US20230037486A1 (en) 2023-02-09
KR20190091308A (ko) 2019-08-05
MA46997A (fr) 2019-10-09
KR102774277B1 (ko) 2025-03-04
ZA201903307B (en) 2020-09-30
US12233133B2 (en) 2025-02-25
US12521448B2 (en) 2026-01-13
US11491240B2 (en) 2022-11-08
JP7455917B2 (ja) 2024-03-26
MD3548091T2 (ro) 2022-03-31
CL2019001447A1 (es) 2019-08-09
TW201818943A (zh) 2018-06-01

Similar Documents

Publication Publication Date Title
MX2019006221A (es) Preparacion de complejos solidos de ciclodextrina para suministro de ingredientes farmaceuticos activos oftalmicos.
MX2018003096A (es) Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma.
BR112018008880A8 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
WO2018022815A3 (en) Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
CR20160477A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso
CL2017003437A1 (es) Formulación solida oral que contiene irinotecán y método de preparación de la misma
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
HK1231376A1 (zh) 局部制剂及其应用
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
MX2017009482A (es) Formulación farmacéutica.
HK1216839A1 (zh) 调整释放制剂
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
EP4364810A3 (en) Topical formulations and uses thereof
CL2018002200A1 (es) Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas.
WO2014204357A3 (ru) Лекарственное средство для лечения кератоконуса
AR103267A1 (es) Método para preparación de liposomas que contienen un ingrediente farmacéutico activo
AR093922A1 (es) Composicion farmaceutica que contiene telmisartan
UY37426A (es) Método para producir una composición farmacéuticamente estable presentada como una solución acuosa
MX381521B (es) Composición farmacéutica antineoplásica estable que comprende temozolomida y un metodo para preparar la composición.
IN2013MU03544A (es)
MX2013009228A (es) Uso de soluciones acuosas de retinoides como vehiculo para la aplicacion terapeutica de farmacos y drogas de uso oftalmologico en la superficie ocular del humano y de otros mamiferos.
BR112016029417A2 (pt) desmopressina estabilizada